Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
Sanuwave Health (NASDAQ: SNWV), a leading provider of FDA-approved wound care products, has successfully refinanced its debt through a new credit facility with J.P. Morgan. The facility includes a $23 million four-year term loan and a $5 million two-year revolving credit facility backed by accounts receivable.
The new arrangement replaces the company's previous $27.5 million debt facility with NH Expansion. At closing, Sanuwave drew approximately $24 million total, including $1 million from the revolving facility. Both facilities carry an interest rate of SOFR +350bp with no prepayment penalties. The remaining balance and transaction costs of approximately $4.8 million were paid using operational cash flow and proceeds from a recent patent sale.
Sanuwave Health (NASDAQ: SNWV), essendo un fornitore leader di prodotti per la cura delle ferite approvati dalla FDA, ha rifinanziato con successo il proprio debito mediante una nuova linea di credito con J.P. Morgan. La linea include un prestito a termine quadriennale da 23 milioni di dollari e una linea di credito revolving di due anni da 5 milioni di dollari garantita da conti clienti. La nuova disposizione sostituisce la precedente linea di debito da 27,5 milioni di dollari con NH Expansion. Al closing, Sanuwave ha tirato circa 24 milioni di dollari in totale, di cui 1 milione dal revolving. Entrambe le linee hanno un tasso di interesse SOFR +350bp senza penali di prepagamento. Il saldo rimanente e i costi di transazione di circa 4,8 milioni di dollari sono stati pagati con flussi di cassa operativi e proventi dalla recente vendita di un brevetto.
Sanuwave Health (NASDAQ: SNWV), un proveedor líder de productos para el cuidado de heridas aprobados por la FDA, ha refinanciado con éxito su deuda mediante una nueva facility de crédito con J.P. Morgan. La facility incluye un préstamo a plazo de cuatro años por 23 millones de dólares y una línea de crédito revolving de dos años de 5 millones de dólares respaldada por cuentas por cobrar.
La nueva disposición reemplaza la anterior facilidad de deuda de 27,5 millones de dólares con NH Expansion. Al cierre, Sanuwave ha retirado aproximadamente 24 millones de dólares en total, incluyendo 1 millón desde la línea revolving. Ambas facilidades tienen una tasa de interés de SOFR +350bp sin penalizaciones por prepago. El saldo restante y los costos de transacción de aproximadamente 4,8 millones de dólares se pagaron con flujo de efectivo operativo y ingresos de la reciente venta de una patente.
J.P. Morgan과의 신규 신용시설을 통해 부채를 성공적으로 재융자한 Sanuwave Health (NASDAQ: SNWV)는 FDA 승인 상처 관리 제품의 선도적 공급업체입니다. 이 시설은 사대년 만기 2,300만 달러의 term loan과 계정매출채권으로 뒷받침되는 2년 만기 500만 달러 revolving credit facility를 포함합니다.
새로운 구조는 NH Expansion와 함께 2750만 달러의 부채 시설를 대체합니다. 마감 시 Sanuwave는 총 2400만 달러를 인출했고, 그중 100만 달러는 revolving에서 나왔습니다. 두 시설 모두 이자율은 SOFR +350bp이며 선불 수수료가 없습니다. 잔액 및 거래 비용 약 480만 달러은 운영 현금 흐름과 최근 특허 매각으로 지급되었습니다.
Sanuwave Health (NASDAQ: SNWV), acteur majeur des produits de soins des plaies approuvés par la FDA, a refinancé avec succès sa dette par le biais d'une nouvelle facilité de crédit avec J.P. Morgan. Cette facilité comprend un prêt à terme quadriennal de 23 millions de dollars et une ligne de crédit revolving de deux ans de 5 millions de dollars garantie par les comptes clients.
La nouvelle organisation remplace l'ancienne facilité d'endettement de 27,5 millions de dollars avec NH Expansion. À la clôture, Sanuwave a puisé environ 24 millions de dollars au total, dont 1 million provenant de la ligne revolving. Les deux facilités portent un taux d'intérêt de SOFR +350bp sans pénalités de prépaiement. Le solde restant et les coûts de transaction d'environ 4,8 millions de dollars ont été payés à partir des flux de trésorerie opérationnels et des recettes tirées de la récente vente d'un brevet.
Sanuwave Health (NASDAQ: SNWV), ein führender Anbieter von von der FDA zugelassenen Wundpflegeprodukten, hat erfolgreich seine Schulden durch eine neue Kreditfazilität mit J.P. Morgan refinanziert. Die Fazilität umfasst ein vierjähriges Term Loan über 23 Millionen Dollar und eine zwei Jahre laufende revolvierende Kreditfazilität über 5 Millionen Dollar, besichert durch Forderungen.
Die neue Vereinbarung ersetzt die bisherige Schuldenfazilität in Höhe von 27,5 Millionen Dollar mit NH Expansion. Zum Abschluss zog Sanuwave insgesamt ca. 24 Millionen Dollar ab, davon 1 Million aus der revolvierenden Fazilität. Beide Fazilitäten tragen einen Zinssatz von SOFR +350bp ohne Vorfälligkeitsentschädigungen. Der verbleibende Saldo und Transaktionskosten von ca. 4,8 Millionen Dollar wurden durch operativen Cashflow und Erlöse aus dem jüngsten Patentverkauf bezahlt.
Sanuwave Health (ناسداك: SNWV)، مقدم رائد لمنتجات رعاية الجروح المعتمدة من FDA، قام بإعادة تمويل ديونه بنجاح من خلال تسهيل ائتماني جديد مع J.P. Morgan. يتضمن التسهيل قرضًا لأجل مدته أربع سنوات بقيمة 23 مليون دولار و تسهيل ائتماني دوّار لمدة سنتين بقيمة 5 ملايين دولار مدعوم من قبل الحسابات المدينة.
هذا الترتيب الجديد يحل محل التسهيل السابق بقيمة 27.5 مليون دولار مع NH Expansion. عند الإغلاق، سانوووڤ سحب ما يقرب من 24 مليون دولار بإجماله، بما في ذلك مليون دولار واحد من التسهيل الدوار. كلا التسهيلين يحملهما معدل فائدة SOFR +350bp بدون غرامات سداد مبكر. الرصيد المتبقي وتكاليف المعاملة البالغة حوالي 4.8 ملايين دولار تم سدادها من التدفقات النقدية التشغيلية وإيرادات من بيع براءة اختراع حديثة.
Sanuwave Health (NASDAQ: SNWV)，是一家FDA批准的伤口护理产品的领先提供商，已通过与 J.P. Morgan 的新信贷额度成功再融资其债务。该额度包括一笔 四年期、2300万美元的定期贷款 和一笔 两年期、500万美元的循环信贷额度，以应收账款作为担保。
新安排取代了此前与 NH Expansion 的 2750万美元债务设施。在成交时，Sanuwave 总计提取约 2400万美元，其中 100万美元 来自循环额度。两项设施的利率均为 SOFR +350bp，无提前还款罚金。剩余余额及交易成本约 480万美元，通过经营性现金流和最近的专利出售所得支付。
- None.
- Company still maintains substantial debt of $24M
- Additional transaction and initiation costs of $1.3M incurred
- Required sale of intravascular shockwave patents to help fund the refinancing
Insights
Sanuwave's refinancing reduces interest burden, improves cash flow, and demonstrates banking confidence in the company's financial health.
Sanuwave's new
The most immediate benefit is the reduced interest rate. While the previous rate wasn't specified, the new SOFR +
The refinancing also reduced total debt by approximately
Perhaps most significant is the elimination of prepayment penalties, giving Sanuwave the freedom to accelerate debt reduction when excess cash is available without incurring additional costs. This aligns with management's stated goal of paying down debt from operating cash flows.
The relationship with J.P. Morgan represents a strong vote of confidence in Sanuwave's financial stability. Major financial institutions typically impose rigorous underwriting standards, suggesting J.P. Morgan sees Sanuwave as creditworthy with sustainable cash flows. This banking relationship could provide additional benefits beyond the current facilities as the company continues to grow.
This refinancing demonstrates proactive financial management and positions Sanuwave to allocate more resources toward growth initiatives rather than debt servicing, potentially accelerating their development in the wound care market.
Credit facility from J.P. Morgan consists of a four-year term loan of
Both the term loan and revolver have an interest rate of SOFR +350bp
The Company drew approximately
Company announces the repayment in full of NH Expansion debt facility with new credit facility from J.P. Morgan and cash on hand
EDEN PRAIRIE, Minn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the successful refinancing of its
The use of proceeds for the
“This refinancing marks a pivotal step in strengthening Sanuwave’s financial position,” said Sanuwave CEO Morgan Frank. “The significant reduction in our interest rate, the reduction of our overall debt load, and a move to a set of ‘no prepayment penalty’ terms all position us to better generate cash flow in support of our ongoing mission to pay down our debt out of operating cash flow. We could not ask for a better lender than J.P. Morgan, whose reputation for global leadership in banking needs no introduction. They have already been a great help, and we look forward to working with them going forward.”
Additional details regarding the terms of the new secured credit facility will be included in a Current Report on Form 8-K that the Company intends to file with the Securities and Exchange Commission within four business days.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to our new secured credit facility, our commercial banking facilities, future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact: investors@sanuwave.com
FAQ
What are the terms of Sanuwave's (SNWV) new credit facility with J.P. Morgan?
How much did Sanuwave (SNWV) reduce its debt through the refinancing?
What is the interest rate on Sanuwave's new J.P. Morgan credit facility?
How did Sanuwave fund the remaining balance of its previous NH Expansion debt?
What is the purpose of Sanuwave's (SNWV) debt refinancing?
